PDE2A and pancreatic adenocarcinoma: However, in several cancers such as CESC, ESCA, CHOL, HNSC, pancreatic adenocarcinoma (PAAD), and skin cutaneous melanoma (SKCM), there was no statistically difference in PDE2A expression throughout the progression of tumors.